Butchertown Clinical Trials' extraordinary growth in FY21

Based on the number of trials and FDA approved drugs and devices, the Butchertown Clinical Trials division of The Eye Care Institute is likely the largest and most successfully privately owned clinical trials site emphasizing ophthalmic clinical trials. It has a national reputation as a superior, trusted, fully compliant and high-enrolling ophthalmic trials site.

Market analysts suggest COVID-19 and the rising prevalence of other diseases will contribute to enormous growth in clinical trials right around the world, and Butchertown Clinical is emerging as one of America's leading providers.

Their FY21 growth was among the highest in the industry, based on online searches for the company and the services it provides.

All of their clinical trials are conducted with the purpose of having the medicine, treatment, implant or device approved by the US Food & Drug Administration (FDA), and their trials have led to fifteen FDA approvals.

Butchertown Clinical has a freestanding clinical trial building on their five-acre medical campus. Their facilities include a procedure room, two medical examination rooms, state-of-the-art diagnostic equipment and a designated monitoring area.

Butchertown Clinical boasts a high - and growing - number of enrolled patients, also known as trial subjects. With an extensive patient databases, and its state-of-the-art scheduling and clinical trial management software systems, Butchertown Clinical can readily search 78,000 active patient charts to identify potential trial subjects by condition, disease and other inclusion/exclusion criteria.

CEO Mark Prussian contributes this year's growth to the company's impeccable data compliance and the dedicated doctors and staff providing excellence in care as a clinical trials option.

"We take health, wellness, alleviating discomfort, and improving vision seriously. We carefully review all trials to make sure the health and well-being of our Louisville, KY area participants are protected," he says.


James Nottingham
Journalist
https://www.afp.com



comtex tracking

COMTEX_413751168/2767/2022-09-05T01:04:17